Both drugs target type 2 diabetes and occasionally weight, but their commercial path and patient reach diverge dramatically
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Webster has spent much of his life involved in competitive athletics
Phase 2 data presented at the American Diabetes Association showed up to 24% weight loss at 48 weeks, approaching bariatric surgery territory
If you're new to exercise, start with simple activities like walking
This can result in sarcopenic obesity , particularly in older or frail populations, and raises new questions about treatment sustainability